Fortrea Holdings Inc. (FTRE) stock surged 5.11% in pre-market trading on Tuesday, despite the company reporting disappointing fourth-quarter 2024 results and issuing weaker-than-expected guidance for 2025.
In its Q4 2024 earnings report, Fortrea disclosed a 1.8% year-over-year decline in revenue to $697 million, primarily due to lower late-stage clinical service fee revenue. The company's adjusted EBITDA margin for the full year 2024 also decreased to 7.5%, down from 8.6% in 2023, impacted by the lower revenues and higher SG&A expenses.
Fortrea's net loss for the full year 2024 ballooned to $271.5 million, a significant increase from the $31.7 million net loss reported in 2023. The company attributed the larger net loss to the impact of pre-spin projects with lower revenue and profitability, as well as higher SG&A costs related to professional fees and exiting transition services with its former parent company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。